ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: FR-PO459

A Budget Impact Model (BIM) for Expanded Haemodialysis (HDx) vs. High-Flux Haemodialysis (HF-HD) in Two Major Public Health Sectors, Kingdom of Saudi Arabia (KSA)

Session Information

Category: Dialysis

  • 801 Dialysis: Hemodialysis and Frequent Dialysis

Authors

  • Fourtounas, Konstantinos, King Salman Armed Forces Hospital, Tabuk, Tabuk, Saudi Arabia
  • Kechrid, Mohamed Ce., Security Forces Hospital Program, Riyadh, Riyadh, Saudi Arabia
  • Alsaqaaby, Mai Fahad, IQVIA Solutions Limited Riyadh, Riyadh, Riyadh, Saudi Arabia
  • Mahsoub, Mohamed, Baxter AG, Dubai, Dubai, United Arab Emirates
  • Henderson, Sam, Baxter AG, Dubai, Dubai, United Arab Emirates
  • Mohamed, Omneya Elsayed Darwish Moustafa, Baxter AG, Dubai, Dubai, United Arab Emirates
  • Karkar, Ayman, Baxter AG, Dubai, Dubai, United Arab Emirates
Background

Chronic Kidney Disease imposes economic costs on healthcare systems. The Saudi Center for Organ Transplantation (SCOT) in 2020 estimated that the number of patients undergoing dialysis (all modalities) is expected to increase by 5% per annum. Accumulation of large-size middle molecules/uremic toxins have been shown to be associated with inflammation, vascular calcification, and increased risk of cardiovascular disease. While conventional HD will clear smaller middle molecules adequately; large middle molecules can be reduced by HDx. Theranova (Baxter Healthcare Corporation, Deerfield, IL USA), a medium cut off dialyzer, allows for better clearance of large middle molecules than traditional HF-HD dialyzers.

Methods

An excel-based BIM was assessed the overall cost of HF-HD patients versus those on HDx over five-years from public payers’ perspectives. Input data were retrieved via a comprehensive literature search and expert interviews. These included epidemiology data, the costs of healthcare resources utilized in dialysis sessions and dialysis related complications management including physician visits, hospitals stay, and medications.

Results

As per 2021 SCOT report, 1,862 Patients are managed in these health Sectors. HF-HD Therapy total cost per patient per year was $15,947 (US Dollars $, USD, $1 = 3.75 Saudi Riyals [SAR]), while the total cost of HDx Therapy per patient per year was $12,019. The overall cost saving per patient per year of $3,928 were driven by reductions in hospitalization, $3,619, followed by reductions in dose of Erythropoietin Stimulating Agents (ESA), $232, per patient per year. Over 5 Years the cost savings for the patients treated in these health sectors was $3.4m.

Conclusion

This study demonstrated that choosing HDx as alternative line of therapy may result in cost savings. In addition to HDx clinical benefits associated with better clearance of large middle molecules, the increased adoption of HDx with Theranova may provide further economic benefit.

Funding

  • Commercial Support – Baxter AG